| Followers | 843 |
| Posts | 123024 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Thursday, January 13, 2022 2:45:43 AM
PCVX sells 5.075M* shares/prefunded warrants @$20.00—a_15%_discount to Monday’s_closing price of $23.61:
https://www.globenewswire.com/news-release/2022/01/13/2366065/0/en/Vaxcyte-Announces-Pricing-of-100-Million-Public-Offering.html
I've long been a skeptic of this company—see, for instance #msg-163165688.
*Assuming exercise of underwriter’s option.
https://www.globenewswire.com/news-release/2022/01/13/2366065/0/en/Vaxcyte-Announces-Pricing-of-100-Million-Public-Offering.html
I've long been a skeptic of this company—see, for instance #msg-163165688.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent PCVX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:12:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:08:31 PM
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 09:37:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:17:46 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:24:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:32:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/07/2026 08:24:11 PM
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:08:55 PM
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults • GlobeNewswire Inc. • 03/23/2026 12:30:00 PM
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate • GlobeNewswire Inc. • 03/18/2026 11:34:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:03:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:16:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:08:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:06:44 AM
